制定核心结局指标集(COS)用于报告成人肺结核抗结核治疗临床试验结局的方案
全球结核病负担仍高,药物敏感和耐药结核的治疗复杂且漫长。历史与近期III期结核试验的报告在结局选择与报告上存在变异,可能影响证据合成与解读。本方案拟通过系统评价已发表试验和试验方案识别结局,通过定性证据系统评价纳入患者重要结局,采用多阶段德尔菲法寻求国际利益相关方共识,最终在线共识会议批准核心结局指标集(COS),过程遵循COS-STAD指南并获COMET支持,研究已注册于COMET数据库(研究2195,2022年10月注册)。
要点
- 结核III期试验结局选择与报告存在变异,可能影响证据合成与解读。
- 方案拟通过系统评价和定性证据系统评价识别结局,采用多阶段德尔菲法达成共识。
- 最终COS将在在线共识会议批准,过程遵循COS-STAD并获COMET支持。
核心结论
- 在结核试验社区实施反映利益相关方最重要结局的COS,有助于确保重要证据快速、清晰、有效地转化为实践,以最大化患者获益。
研究设计与样本
- 本方案拟从已发表试验和试验方案的系统评价中识别成人肺结核III期治疗试验所用结局,并按关键领域分组。
- 将进行定性证据系统评价,以了解对结核患者重要的结局。
- 将通过多阶段德尔菲法从代表关键利益相关方群体的国际专家组寻求共识。
- 最终COS将在在线共识会议上批准,并经SSC批准,过程遵循COS-STAD指南并获COMET支持。
- 研究已注册于COMET核心结局指标集数据库(研究2195,2022年10月注册)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The global burden of tuberculosis (TB) remains high, and treatment of both drug-susceptible and drug-resistant diseases is complex and prolonged. International clinical trial networks and public-private partnerships are beginning to deliver advances in TB treatment, and collaborative data-sharing efforts are being promoted to improve the transparency and scrutiny of the evidence used in formulating treatment guidelines and public health policies. Empirical studies have identified variability in the selection and reporting of clinical trial outcomes in historical and recent phase III trial reports and protocols in TB. This variability could affect the synthesis of evidence and interpretation by practitioners, regulators, and policymakers. METHODS AND ANALYSIS: A comprehensive list of outcomes used in phase III treatment trials of pulmonary TB in adults, grouped according to key domains, will be identified from systematic reviews of published trials and trial protocols. A systematic review of qualitative evidence will inform outcomes important to people diagnosed with TB. Consensus will be sought from an international panel of participants representing key stakeholder groups using a multi-stage Delphi process. The final COS identified from the Delphi survey will be ratified at an online consensus meeting and approved by the SSC. The process will be conducted according to the Core Outcome Set-STAndards for Development (COS-STAD) guidance and with the support of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative. DISCUSSION: A COS implemented in the TB trials community that reflects the outcomes most important to stakeholders would help ensure that important evidence is translated rapidly, clearly, and effectively into practice to maximise patient benefit. TRIAL REGISTRATION: The study has been registered with the COMET database of core outcome sets (study 2195, registered October 2022).
引用
- Thomas R, Harman NL, Williamson PR, et al. Protocol for the development of a Core Outcome Set (COS) for reporting outcomes of clinical trials of anti-tuberculosis treatment in adults with pulmonary tuberculosis. Trials. 2025. PMID: 41254665. doi:10.1186/s13063-025-09224-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。